Paratek Pharmaceuticals

About:

Paratek Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of innovative therapies.

Website: http://paratekpharma.com/

Twitter/X: ParatekPharma

Top Investors: The Baupost Group, Abingworth, D. E. Shaw & Co., Biomedical Advanced Research and Development Authority (BARDA), Omega Funds

Description:

Paratek Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon its expertise in novel tetracycline chemistry. Paratek's lead product candidate, omadacycline, is a new tetracycline-derived, broad-spectrum antibiotic being developed in both oral tablet and intravenous formulations for use as a first-line monotherapy antibiotic for ABSSSI, CABP, urinary tract infections (UTI) and other serious community-acquired bacterial infections, particularly when antibiotic resistance is of concern to prescribing physicians. Omadacycline has received Qualified Infectious Disease Product (QIDP) designation by the U.S. Food and Drug Administration for both the oral and intravenous formulations in all three of these infectious disease categories. Paratek has Special Protocol Assessment agreements with the FDA for the phase 3 trials planned in ABSSSI and CABP.